N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes

Frontiers in Pharmacology

Volumn 5 APR, Issue , 2014, Pages

  Kanasaki, Keizo ^a   Nagai, Takako ^a   Nitta, Kyoko ^a   Kitada, Munehiro ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

ACE I; Arb; Diabetes mellitus; Fibroblast; Kidney fibrosis

Indexed keywords

BRADYKININ; CAPTOPRIL; ENALAPRILAT; LISINOPRIL; SERASPENIDE; TRANDOLAPRIL;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; APOPTOSIS; CARBOXY TERMINAL SEQUENCE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; G1 PHASE CELL CYCLE CHECKPOINT; INFLAMMATION; KIDNEY FIBROSIS; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; S PHASE CELL CYCLE CHECKPOINT;

EID: 84901002157     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00070     Document Type: Review

References (138)

1. Acharya, K. R., Sturrock, E. D., Riordan, J. F., and Ehlers, M. R. (2003). Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. 2, 891-902. doi: 10.1038/nrd1227
2. Akif, M., Ntai, I., Sturrock, E. D., Isaac, R. E., Bachmann, B. O., and Acharya, K. R. (2010). Crystal structure of a phosphonotripeptide K-26 in complex with angiotensin converting enzyme homologue (AnCE) from Drosophila melanogaster. Biochem. Biophys. Res. Commun. 398, 532-536. doi: 10.1016/j.bbrc.2010.06.113
3. Anthony, C. S., Corradi, H. R., Schwager, S. L., Redelinghuys, P., Georgiadis, D., Dive, V., et al. (2010). The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407. J. Biol. Chem. 285, 35685-35693. doi: 10.1074/jbc. M110.167866
4. Azizi, M., Rousseau, A., Ezan, E., Guyene, T. T., Michelet, S., Grognet, J. M., et al. (1996). Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 97, 839-844. doi: 10.1172/JCI118484
5. Barnes, J. L., and Gorin, Y. (2011). Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 79, 944-956. doi: 10.1038/ki.2010.516
6. Bernstein, K. E., Shen, X. Z., Gonzalez-Villalobos, R. A., Billet, S., Okwan-Duodu, D., Ong, F. S., et al. (2011). Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr. Opin. Pharmacol. 11, 105-111. doi: 10.1016/j.coph.2010.11.001
7. Bi, S., Hughes, T., Bungey, J., Chase, A., De Fabritiis, P., and Goldman, J. M. (1992). p53 in chronic myeloid leukemia cell lines. Leukemia 6, 839-842.
8. Bingham, R. J., Dive, V., Phillips, S. E., Shirras, A. D., and Isaac, R. E. (2006). Structural diversity of angiotensin-converting enzyme. FEBS J. 273, 362-373. doi: 10.1111/j.1742-4658.2005.05069.x
9. Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., and Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432, 466-472. doi: 10.1038/nature03000
10. Bogden, A. E., Carde, P., De Paillette, E. D., Moreau, J. P., Tubiana, M., and Frindel, E. (1991). Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation. Ann. N. Y. Acad. Sci. 628, 126-139. doi: 10.1111/j.1749-6632.1991.tb17230.x
11. Border, W. A., and Noble, N. A. (1994). Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292. doi: 10.1056/NEJM199411103311907
12. Brenner, B. M., Cooper, M. E., De Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H. H., et al. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345:861-869. doi: 10.1056/NEJMoa011161
13. Bullard, K. M., Longaker, M. T., and Lorenz, H. P. (2003). Fetal wound healing: current biology. World J. Surg. 27, 54-61. doi: 10.1007/s00268-002-6737-2
14. Cashman, J. D., Eaves, A. C., and Eaves, C. J. (1994). The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism. Blood 84, 1534-1542.
15. Castoldi, G., Di Gioia, C. R., Bombardi, C., Preziuso, C., Leopizzi, M., Maestroni, S., et al. (2013). Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Am. J. Nephrol. 37, 65-73. doi: 10.1159/000346116
16. Cavasin, M. A., Liao, T. D., Yang, X. P., Yang, J. J., and Carretero, O. A. (2007). Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 50, 130-136. doi: 10.1161/HYPERTENSIONAHA.106.084103
17. Cavasin, M. A., Rhaleb, N. E., Yang, X. P., and Carretero, O. A. (2004). Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43, 1140-1145. doi: 10.1161/01.HYP.0000126172.01673.84
18. Chen, P. L., Chen, Y. M., Bookstein, R., and Lee, W. H. (1990). Genetic mechanisms of tumor suppression by the human p53 gene. Science 250, 1576-1580. doi: 10.1126/science.2274789
19. Chen, P. Y., Qin, L., Barnes, C., Charisse, K., Yi, T., Zhang, X., et al. (2012). FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2, 1684-1696. doi: 10.1016/j.celrep.2012.10.021
20. Chen, Y. W., Liu, B. W., Zhang, Y. J., Chen, Y. W., Dong, G. F., Ding, X. D., et al. (2010). Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver. J. Hepatol. 53, 528-536. doi: 10.1016/j.jhep.2010.03.027
21. Choi, K., Lee, K., Ryu, S. W., Im, M., Kook, K. H., and Choi, C. (2012). Pirfenidone inhibits transforming growth factor-beta1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol. Vis. 18, 1010-1020.
22. Coates, D., Isaac, R. E., Cotton, J., Siviter, R., Williams, T. A., Shirras, A., et al. (2000). Functional conservation of the active sites of human and Drosophila angiotensin I-converting enzyme. Biochemistry 39, 8963-8969. doi: 10.1021/bi000593q
23. Cornell, M. J., Williams, T. A., Lamango, N. S., Coates, D., Corvol, P., Soubrier, F., et al. (1995). Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from Drosophila melanogaster. J. Biol. Chem. 270, 13613-13619. doi: 10.1074/jbc.270.23.13613
24. Coutton, C., Guigon, M., Bohbot, A., Ferrani, K., and Oberling, F. (1994). Photoprotection of normal human hematopoietic progenitors by the tetrapeptide N-AcSDKP. Exp. Hematol. 22, 1076-1080.
25. Coward, W. R., Saini, G., and Jenkins, G. (2010). The pathogenesis of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 4, 367-388. doi: 10.1177/1753465810379801
26. Deeg, H. J., Seidel, K., Hong, D. S., Yu, C., Huss, R., Schuening, F. G., et al. (1997). In vivo radioprotective effect of AcSDKP on canine myelopoiesis. Ann. Hematol. 74, 117-122. doi: 10.1007/s002770050268
27. Dooley, R., Harvey, B. J., and Thomas, W. (2011). The regulation of cell growth and survival by aldosterone. Front. Biosci. 16:440-457. doi: 10.2741/3697
28. Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., et al. (2001). Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 12477-12480. doi: 10.1074/jbc. C100008200
29. Esther, C. R., Marino, E. M., Howard, T. E., Machaud, A., Corvol, P., Capecchi, M. R., et al. (1997). The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J. Clin. Invest. 99, 2375-2385. doi: 10.1172/JCI119419
30. Feinstein, E., Cimino, G., Gale, R. P., Alimena, G., Berthier, R., Kishi, K., et al. (1991). p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. U.S.A. 88, 6293-6297. doi: 10.1073/pnas.88.14.6293
31. Folkman, J. (2007). Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286. doi: 10.1038/nrd2115
32. Fromes, Y., Liu, J. M., Kovacevic, M., Bignon, J., and Wdzieczak-Bakala, J. (2006). The tetrapeptide acetyl-serine-aspartyl-lysine-proline improves skin flap survival and accelerates wound healing. Wound Repair Regen. 14, 306-312. doi: 10.1111/j.1743-6109.2006.00125.x
33. Fuchs, S., Frenzel, K., Hubert, C., Lyng, R., Muller, L., Michaud, A., et al. (2005). Male fertility is dependent on dipeptidase activity of testis ACE. Nat. Med. 11, 1140-1142. doi: 10.1038/nm1105-1140
34. Fuchs, S., Xiao, H. D., Cole, J. M., Adams, J. W., Frenzel, K., Michaud, A., et al. (2004). Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J. Biol. Chem. 279, 15946-15953. doi: 10.1074/jbc. M400149200
35. Fuchs, S., Xiao, H. D., Hubert, C., Michaud, A., Campbell, D. J., Adams, J. W., et al. (2008). Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267-274. doi: 10.1161/HYPERTENSIONAHA.107.097865
36. Gieling, R. G., Burt, A. D., and Mann, D. A. (2008). Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin. Liver Dis. 12, 915-937, xi. doi: 10.1016/j.cld.2008.07.001
37. Gonzalez, G. E., Rhaleb, N. E., Nakagawa, P., Liao, T. D., Liu, Y., Leung, P., et al. (2014). N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats. Clin. Sci. (Lond.) 126, 85-94. doi: 10.1042/CS20120619
38. Grande, M. T., and Lopez-Novoa, J. M. (2009). Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat. Rev. Nephrol. 5, 319-328. doi: 10.1038/nrneph.2009.74
39. Grillon, C., Bonnet, D., Mary, J. Y., Lenfant, M., Najman, A., and Guigon, M. (1993). The tetrapeptide AcSerAspLysPro (Seraspenide), a hematopoietic inhibitor, may reduce the in vitro toxicity of 3'-azido-3'-deoxythymidine to human hematopoietic progenitors. Stem Cells 11, 455-464. doi: 10.1002/stem.5530110513
40. Grillon, C., Rieger, K., Bakala, J., Schott, D., Morgat, J. L., Hannappel, E., et al. (1990). Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Lett. 274, 30-34. doi: 10.1016/0014-5793(90)81322-F
41. Gronroos, E., Hellman, U., Heldin, C. H., and Ericsson, J. (2002). Control of Smad7 stability by competition between acetylation and ubiquitination. Mol. Cell 10, 483-493. doi: 10.1016/S1097-2765(02)00639-1
42. Hannappel, E. (2010). Thymosin beta4 and its posttranslational modifications. Ann. N. Y. Acad. Sci. 1194, 27-35. doi: 10.1111/j.1749-6632.2010.05485.x
43. He, J., Xu, Y., Koya, D., and Kanasaki, K. (2013). Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin. Exp. Nephrol. 17, 488-497. doi: 10.1007/s10157-013-0781-0
44. Hills, C. E., and Squires, P. E. (2011). The role of TGF-beta and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 22, 131-139. doi: 10.1016/j.cytogfr.2011.06.002
45. Houard, X., Williams, T. A., Michaud, A., Dani, P., Isaac, R. E., Shirras, A. D., et al. (1998). The Drosophila melanogaster-related angiotensin-I-converting enzymes Acer and Ance - distinct enzymic characteristics and alternative expression during pupal development. Eur. J. Biochem. 257, 599-606. doi: 10.1046/j.1432-1327.1998.2570599.x
46. Howard, T. E., Shai, S. Y., Langford, K. G., Martin, B. M., and Bernstein, K. E. (1990). Transcription of testicular angiotensin-converting enzyme (ACE) is initiated within the 12th intron of the somatic ACE gene. Mol. Cell. Biol. 10, 4294-4302.
47. Hubert, C., Houot, A. M., Corvol, P., and Soubrier, F. (1991). Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem. 266, 15377-15383.
48. Huff, T., Muller, C. S., Otto, A. M., Netzker, R., and Hannappel, E. (2001). beta-Thymosins, small acidic peptides with multiple functions. Int. J. Biochem. Cell Biol. 33, 205-220. doi: 10.1016/S1357-2725(00)00087-X
49. Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., et al. (2010). Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419-430. doi: 10.1016/S0140-6736(10)60576-4
50. Iwamoto, N., Xano, H. J., Yoshioka, T., Shiraga, H., Nitta, K., Muraki, T., et al. (2000). Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells. Life Sci. 66, PL221-PL226. doi: 10.1016/S0024-3205(00)00460-4
51. Junot, C., Gonzales, M. F., Ezan, E., Cotton, J., Vazeux, G., Michaud, A., et al. (2001). RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J. Pharmacol. Exp. Ther. 297, 606-611.
52. Kanasaki, K., Haneda, M., Sugimoto, T., Shibuya, K., Isono, M., Isshiki, K., et al. (2006). N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators. Biochem. Biophys. Res. Commun. 342, 758-765. doi: 10.1016/j.bbrc.2006.02.019
53. Kanasaki, K., Kitada, M., and Koya, D. (2012). Pathophysiology of the aging kidney and therapeutic interventions. Hypertens. Res. 35, 1121-1128. doi: 10.1038/hr.2012.159
54. Kanasaki, K., Koya, D., Sugimoto, T., Isono, M., Kashiwagi, A., and Haneda, M. (2003). N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J. Am. Soc. Nephrol. 14, 863-872. doi: 10.1097/01.ASN.0000057544.95569.EC
55. Kanasaki, K., Taduri, G., and Koya, D. (2013). Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front. Endocrinol. 4:7. doi: 10.3389/fendo.2013.00007
56. Kanasaki, M., Nagai, T., Kitada, M., Koya, D., and Kanasaki, K. (2011). Elevation of the anti-fibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair 4:25. doi: 10.1186/1755-1536-4-25
57. Koutrafouri, V., Leondiadis, L., Avgoustakis, K., Livaniou, E., Czarnecki, J., Ithakissios, D. S., et al. (2001). Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim. Biophys. Acta 1568, 60-66. doi: 10.1016/S0304-4165(01)00200-8
58. Krege, J. H., John, S. W., Langenbach, L. L., Hodgin, J. B., Hagaman, J. R., Bachman, E. S., et al. (1995). Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375, 146-148. doi: 10.1038/375146a0
59. Kroger, W. L., Douglas, R. G., O'Neill, H. G., Dive, V., and Sturrock, E. D. (2009). Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry 48, 8405-8412. doi: 10.1021/bi9011226
60. Kurisaki, A., Kose, S., Yoneda, Y., Heldin, C. H., and Moustakas, A. (2001). Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. Mol. Biol. Cell 12, 1079-1091. doi: 10.1091/mbc.12.4.1079
61. Kwakernaak, A. J., Waanders, F., Slagman, M. C., Dokter, M. M., Laverman, G. D., De Boer, R. A., et al. (2013). Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients. J. Hypertens. 31, 2425-2432. doi: 10.1097/HJH.0b013e328364f5de
62. Lan, H. Y. (2011). Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 7, 1056-1067. doi: 10.7150/ijbs.7.1056
63. Langford, K. G., Shai, S. Y., Howard, T. E., Kovac, M. J., Overbeek, P. A., and Bernstein, K. E. (1991). Transgenic mice demonstrate a testis-specific promoter for angiotensin-converting enzyme. J. Biol. Chem. 266, 15559-15562.
64. LeBleu, V. S., Taduri, G., O'Connell, J., Teng, Y., Cooke, V. G., Woda, C., et al. (2013). Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053. doi: 10.1038/nm.3218
65. Lenfant, M., Wdzieczak-Bakala, J., Guittet, E., Prome, J. C., Sotty, D., and Frindel, E. (1989). Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc. Natl. Acad. Sci. U.S.A. 86, 779-782. doi: 10.1073/pnas.86.3.779
66. Lewis, E. J., Hunsicker, L. G., Bain, R. P., and Rohde, R. D. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329:1456-1462. doi: 10.1056/NEJM199311113292004
67. Li, P., Xiao, H. D., Xu, J., Ong, F. S., Kwon, M., Roman, J., et al. (2010). Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. Am. J. Pathol. 177, 1113-1121. doi: 10.2353/ajpath.2010.081127
68. Lin, C. X., Rhaleb, N. E., Yang, X. P., Liao, T. D., D'Ambrosio, M. A., and Carretero, O. A. (2008). Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension. Am. J. Physiol. Heart Circ. Physiol. 295, H1253-H1261. doi: 10.1152/ajpheart.00481.2008
69. Liu, J. M., Bignon, J., Ilic, V., Briscoe, C., Lallemand, J. Y., Riches, A., et al. (2006). Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development. Leuk. Lymphoma 47, 1915-1920. doi: 10.1080/10428190600688131
70. Liu, J. M., Garcia-Alvarez, M. C., Bignon, J., Kusinski, M., Kuzdak, K., Riches, A., et al. (2010). Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in neoplastic diseases. Ann. N. Y. Acad. Sci. 1194, 53-59. doi: 10.1111/j.1749-6632.2010.05488.x
71. Liu, J. M., Gora-Tybor, J., Grzybowska-Izydorczyk, O., Bignon, J., Robak, T., and Wdzieczak-Bakala, J. (2009a). Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies. Leuk. Lymphoma 50, 2096-2097. doi: 10.3109/10428190903331074
72. Liu, Y. H., D'Ambrosio, M., Liao, T. D., Peng, H., Rhaleb, N. E., Sharma, U., et al. (2009b). N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am. J. Physiol. Heart Circ. Physiol. 296, H404-H412. doi: 10.1152/ajpheart.00747.2008
73. Liu, J. M., Kusinski, M., Ilic, V., Bignon, J., Hajem, N., Komorowski, J., et al. (2008). Overexpression of the angiogenic tetrapeptide AcSDKP in human malignant tumors. Anticancer. Res. 28, 2813-2817.
74. Liu, J. M., Lawrence, F., Kovacevic, M., Bignon, J., Papadimitriou, E., Lallemand, J. Y., et al. (2003). The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 101, 3014-3020. doi: 10.1182/blood-2002-07-2315
75. Liu, Y. (2011). Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 7, 684-696. doi: 10.1038/nrneph.2011.149
76. Macconi, D., Tomasoni, S., Romagnani, P., Trionfini, P., Sangalli, F., Mazzinghi, B., et al. (2012). MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J. Am. Soc. Nephrol. 23, 1496-1505. doi: 10.1681/ASN.2011121144
77. Mackensen-Haen, S., Bader, R., Grund, K. E., and Bohle, A. (1981). Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin. Nephrol. 15, 167-171.
78. Macours, N., and Hens, K. (2004). Zinc-metalloproteases in insects: ACE and ECE. Insect Biochem. Mol. Biol. 34, 501-510. doi: 10.1016/j.ibmb.2004.03.007
79. Malinda, K. M., Goldstein, A. L., and Kleinman, H. K. (1997). Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 11, 474-481.
80. Meran, S., and Steadman, R. (2011). Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol. 92, 158-167. doi: 10.1111/j.1365-2613.2011.00764.x
81. Miyazono, K. (2000). TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev. 11, 15-22. doi: 10.1016/S1359-6101(99)00025-8
82. Nagai, T., Kanasaki, M., Srivastava, S., Nakamura, Y., Ishigaki, Y., Kitada, M., et al. (2014). N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. Biomed. Res. Int. 2014:696475. doi: 10.1155/2014/696475
83. Nakagawa, P., Liu, Y., Liao, T. D., Chen, X., Gonzalez, G. E., Bobbitt, K. R., et al. (2012). Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats. Am. J. Physiol. Heart Circ. Physiol. 303, H1114-H1127. doi: 10.1152/ajpheart.00300.2011
84. Nakao, A., Afrakhte, M., Moren, A., Nakayama, T., Christian, J. L., Heuchel, R., et al. (1997). Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389, 631-635. doi: 10.1038/39369
85. Nath, K. A. (1992). Tubulointerstitial changes as a major determinant in the progression of renal damage. Am. J. Kidney Dis. 20, 1-17.
86. Nyberg, P., Xie, L., and Kalluri, R. (2005). Endogenous inhibitors of angiogenesis. Cancer Res. 65, 3967-3979. doi: 10.1158/0008-5472.CAN-04-2427
87. Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., et al. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes. Res. Clin. Pract. 28, 103-117. doi: 10.1016/0168-8227(95)01064-K
88. Omata, M., Taniguchi, H., Koya, D., Kanasaki, K., Sho, R., Kato, Y., et al. (2006). N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J. Am. Soc. Nephrol. 17, 674-685. doi: 10.1681/ASN.2005040385
89. Parving, H. H. (2001). Diabetic nephropathy: prevention and treatment. Kidney Int. 60, 2041-2055. doi: 10.1046/j.1523-1755.2001.00020.x
90. Peng, H., Carretero, O. A., Liao, T. D., Peterson, E. L., and Rhaleb, N. E. (2007). Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 49, 695-703. doi: 10.1161/01.HYP.0000258406.66954.4f
91. Peng, H., Carretero, O. A., Peterson, E. L., and Rhaleb, N. E. (2010). Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 298, H1357-H1364. doi: 10.1152/ajpheart.00464.2009
92. Peng, H., Carretero, O. A., Raij, L., Yang, F., Kapke, A., and Rhaleb, N. E. (2001). Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 37, 794-800. doi: 10.1161/01.HYP.37.2.794
93. Philp, D., Huff, T., Gho, Y. S., Hannappel, E., and Kleinman, H. K. (2003). The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 17, 2103-2105. doi: 10.1096/fj.03-0121fje
94. Pokharel, S., Rasoul, S., Roks, A. J., Van Leeuwen, R. E., Van Luyn, M. J., Deelman, L. E., et al. (2002). N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 40, 155-161. doi: 10.1161/01.HYP.0000025880.56816.FA
95. Pradelles, P., Frobert, Y., Creminon, C., Ivonine, H., and Frindel, E. (1991). Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues. FEBS Lett. 289, 171-175. doi: 10.1016/0014-5793(91)81062-D
96. Pradelles, P., Frobert, Y., Creminon, C., Liozon, E., Masse, A., and Frindel, E. (1990). Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem. Biophys. Res. Commun. 170, 986-993. doi: 10.1016/0006-291X(90)90489-A
97. RamachandraRao, S. P., Zhu, Y., Ravasi, T., Mcgowan, T. A., Toh, I., Dunn, S. R., et al. (2009). Pirfenidone is renoprotective in diabetic kidney disease. J. Am. Soc. Nephrol. 20, 1765-1775. doi: 10.1681/ASN.2008090931
98. Redd, M. J., Cooper, L., Wood, W., Stramer, B., and Martin, P. (2004). Wound healing and inflammation: embryos reveal the way to perfect repair. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 777-784. doi: 10.1098/rstb.2004.1466
99. Remuzzi, G., Schieppati, A., and Ruggenenti, P. (2002). Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145-1151. doi: 10.1056/NEJMcp011773
100. Rhaleb, N. E., Peng, H., Harding, P., Tayeh, M., Lapointe, M. C., and Carretero, O. A. (2001a). Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 37, 827-832. doi: 10.1161/01.HYP.37.3.827
101. Rhaleb, N. E., Peng, H., Yang, X. P., Liu, Y. H., Mehta, D., Ezan, E., et al. (2001b). Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation 103, 3136-3141. doi: 10.1161/01.CIR.103.25.3136
102. Risdon, R. A., Sloper, J. C., and De Wardener, H. E. (1968). Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet 2:363-366. doi: 10.1016/S0140-6736(68)90589-8
103. Ritz, E., Rychlik, I., Locatelli, F., and Halimi, S. (1999). End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 34, 795-808. doi: 10.1016/S0272-6386(99)70035-1
104. Rodriguez-Iturbe, B., and Garcia Garcia, G. (2010). The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin. Pract. 116, c81-c88. doi: 10.1159/000314656
105. Rousseau, A., Michaud, A., Chauvet, M. T., Lenfant, M., and Corvol, P. (1995). The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270, 3656-3661. doi: 10.1074/jbc.270.8.3656
106. Schainuck, L. I., Striker, G. E., Cutler, R. E., and Benditt, E. P. (1970). Structural-functional correlations in renal disease. II. The correlations. Hum. Pathol. 1, 631-641. doi: 10.1016/S0046-8177(70)80061-2
107. Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., et al. (2011). Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144-1151. doi: 10.1681/ASN.2010101049
108. Sharma, U., Rhaleb, N. E., Pokharel, S., Harding, P., Rasoul, S., Peng, H., et al. (2008). Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am. J. Physiol. Heart Circ. Physiol. 294, H1226-H1232. doi: 10.1152/ajpheart.00305.2007
109. Shibuya, K., Kanasaki, K., Isono, M., Sato, H., Omata, M., Sugimoto, T., et al. (2005). N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes Metab. Res. Rev. 54, 838-845. doi: 10.2337/diabetes.54.3.838
110. Smart, N., Risebro, C. A., Melville, A. A., Moses, K., Schwartz, R. J., Chien, K. R., et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445, 177-182. doi: 10.1038/nature05383
111. Srivastava, S. P., Koya, D., and Kanasaki, K. (2013). MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. Biomed. Res. Int. 2013:125469. doi: 10.1155/2013/125469
112. Stephan, J., Melaine, N., Ezan, E., Hakovirta, H., Maddocks, S., Toppari, J., et al. (2000). Source, catabolism and role of the tetrapeptide N-acetyl-ser-asp-lys-Pro within the testis. J. Cell Sci. 113(Pt 1), 113-121.
113. Striker, G. E., Schainuck, L. I., Cutler, R. E., and Benditt, E. P. (1970). Structural-functional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum. Pathol. 1, 615-630. doi: 10.1016/S0046-8177(70)80060-0
114. Strutz, F., and Zeisberg, M. (2006). Renal fibroblasts and myofibroblasts in chronic kidney disease. J. Am. Soc. Nephrol. 17, 2992-2998. doi: 10.1681/ASN.2006050420
115. Suzuki, C., Murakami, G., Fukuchi, M., Shimanuki, T., Shikauchi, Y., Imamura, T., et al. (2002). Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J. Biol. Chem. 277, 39919-39925. doi: 10.1074/jbc. M201901200
116. Takakuta, K., Fujimori, A., Chikanishi, T., Tanokura, A., Iwatsuki, Y., Yamamoto, M., et al. (2010). Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur. J. Pharmacol. 629, 118-124. doi: 10.1016/j.ejphar.2009.12.011
117. The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986. doi: 10.1056/NEJM199309303291401
118. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865. doi: 10.1016/S0140-6736(98)07037-8
119. Vazeux, G., Cotton, J., Cuniasse, P., and Dive, V. (2001). Potency and selectivity of RXP407 on human, rat, and mouse angiotensin-converting enzyme. Biochem. Pharmacol. 61, 835-841. doi: 10.1016/S0006-2952(01)00550-0
120. Vegter, S., Perna, A., Postma, M. J., Navis, G., Remuzzi, G., and Ruggenenti, P. (2012). Sodium intake, ACE inhibition, and progression to ESRD. J. Am. Soc. Nephrol. 23, 165-173. doi: 10.1681/ASN.2011040430
121. Viswanathan, V. (1999). Type 2 diabetes and diabetic nephropathy in India - magnitude of the problem. Nephrol. Dial. Transplant. 14, 2805-2807. doi: 10.1093/ndt/14.12.2805
122. Waeckel, L., Bignon, J., Liu, J. M., Markovits, D., Ebrahimian, T. G., Vilar, J., et al. (2006). Tetrapeptide AcSDKP induces postischemic neovascularization through monocyte chemoattractant protein-1 signaling. Arterioscler. Thromb. Vasc. Biol. 26, 773-779. doi: 10.1161/01.ATV.0000203510.96492.14
123. Wang, D., Carretero, O. A., Yang, X. Y., Rhaleb, N. E., Liu, Y. H., Liao, T. D., et al. (2004). N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am. J. Physiol. Heart Circ. Physiol. 287, H2099-H2105. doi: 10.1152/ajpheart.00592.2004
124. Wang, M., Liu, R., Jia, X., Mu, S., and Xie, R. (2010). N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats. Int. J. Mol. Med. 26, 795-801.
125. Watanabe, T., Brown, G. S., Kelsey, L. S., Yan, Y., Jackson, J. D., Ewel, C., et al. (1996). In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation. Exp. Hematol. 24, 713-721.
126. Wdzieczak-Bakala, J., Fache, M. P., Lenfant, M., Frindel, E., and Sainteny, F. (1990). AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture. Leukemia 4, 235-237.
127. Wei, L., Alhenc-Gelas, F., Corvol, P., and Clauser, E. (1991). The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266, 9002-9008.
128. Wierenga, P. K., Brenner, M. K., and Konings, A. W. (1998). Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression. Bone Marrow Transplant. 21, 73-78. doi: 10.1038/sj.bmt.1701045
129. Wierenga, P. K., and Konings, A. W. (1994). Seraspenide (AcSDKP) mediated protection of hematopoietic stem cells in a hyperthermic purging protocol. Prog. Clin. Biol. Res. 389, 189-195.
130. Wierenga, P. K., Setroikromo, R., Vellenga, E., and Kampinga, H. H. (2000). Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH(3). Br. J. Haematol. 111, 1145-1152. doi: 10.1046/j.1365-2141.2000.02469.x
131. Wrana, J. L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., et al. (1992). TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003-1014. doi: 10.1016/0092-8674(92)90395-S
132. Wynn, T. A. (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117, 524-529. doi: 10.1172/JCI31487
133. Xiao, Z., Liu, X., and Lodish, H. F. (2000). Importin beta mediates nuclear translocation of Smad 3. J. Biol. Chem. 275, 23425-23428. doi: 10.1074/jbc. C000345200
134. Xu, H., Yang, F., Sun, Y., Yuan, Y., Cheng, H., Wei, Z., et al. (2012). A new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosis. PLoS ONE 7:e40301. doi: 10.1371/journal.pone.0040301
135. Yang, F., Yang, X. P., Liu, Y. H., Xu, J., Cingolani, O., Rhaleb, N. E., et al. (2004). Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 43, 229-236. doi: 10.1161/01.HYP.0000107777.91185.89
136. Zeisberg, M., and Duffield, J. S. (2010). Resolved: EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 21, 1247-1253. doi: 10.1681/ASN.2010060616
137. Zisman, L. S. (1998). Inhibiting tissue angiotensin-converting enzyme: a pound of flesh without the blood? Circulation 98, 2788-2790. doi: 10.1161/01.CIR.98.25.2788
138. Zuo, Y., Chun, B., Potthoff, S. A., Kazi, N., Brolin, T. J., Orhan, D., et al. (2013). Thymosin beta4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int. 84, 1166-1175. doi: 10.1038/ki.2013.209